Anixa Biosciences Shares Tumble Following Clinical Data Release

Anixa Biosciences US03528H1095

Shares of Anixa Biosciences experienced a sharp sell-off in Friday's trading session, closing at $3.58. This represented a decline of approximately 25% from the previous day's closing price. The downward move followed the company's presentation of final Phase 1 trial data for its breast cancer vaccine at the San Antonio Breast Cancer Symposium (SABCS), prompting questions about the market's negative reaction to seemingly positive results.

The clinical data presented indicated that 74% of participants across three cohorts demonstrated a protocol-defined immune response against the target antigen, α‑Lactalbumin. Investigators determined the vaccine to be safe and well-tolerated at the Maximum Tolerated Dose (MTD), with no significant safety alarms reported.

Despite these findings, investor sentiment turned sharply negative. The equity had initially rallied in after-hours trading on Thursday, briefly surpassing $5.50. However, Friday's session was characterized by high volatility and a sustained downtrend that erased those gains. This price action suggests that market participants may have been anticipating more advanced efficacy signals, moving beyond the standard Phase 1 endpoints of safety and immunogenicity that were reported.

Key Data Points:
* Immune response rate of 74% observed across three patient cohorts.
* Favorable safety profile established at the MTD.
* Friday's closing share price: $3.58.
* Brief after-hours peak above $5.50 reached on Thursday.
* Phase 2 trial initiation is anticipated for 2025; IND transfer activities have been ongoing since August 2025.

Technical and Strategic Context

This decline returns the stock to the lower end of its trading range from the second half of 2025, though it remains above its 52-week low of approximately $2.07. Such pronounced volatility is not uncommon for clinical-stage biotechnology companies, where data readouts are often perceived as binary events for valuation. Prior to this event, the company's board had authorized a stock repurchase program of up to $5 million in July, an action previously interpreted as a sign of management confidence.

Looking ahead, the company's leadership is scheduled to participate in a fireside chat hosted by Water Tower Research on Monday, December 15. This event will likely address several critical topics for investors:
* Further clarification on the Phase 1 data details to provide context for the market's reaction.
* Concrete confirmation regarding the planned 2025 timeline for initiating the Phase 2 study.
* Progress updates on the ovarian cancer CAR-T program and related development schedules.

From a technical analysis perspective, the share price has breached near-term support levels. The $3.50 price point is now viewed as a key reference zone for the week ahead. Clear confirmation of the Phase 2 start date during Monday's discussion is expected to be a immediate catalyst for the stock.